The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

• ClinicalTrials.gov Identifier: NCT00487162
• Recruitment Status: Terminated
• First Posted: June 15, 2007
• Results First Posted: April 3, 2014
• Last Update Posted: November 8, 2016
• Sponsor: University of Medicine and Dentistry of New Jersey
• Information provided by (Responsible Party): Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey )

Study Description

Brief Summary:

Surgery induces a stress effect on the body partially through a catabolic energy state. In turn, glucose levels may rise to levels which have been associated with major morbidity (Golden, 1999) and mortality (Ouattara, 2005). An increasing body of evidence suggests that intensive insulin therapy for tight control of blood glucose levels in certain surgical and critical care patient populations may improve mortality and selected morbidity outcomes when compared to those patients receiving conventional insulin therapy and blood glucose management. More specifically, poor intra-operative blood glucose control is associated with worse outcome after cardiac surgery. Intensive insulin therapy with tight blood glucose control in surgical patients while in the ICU may reduce morbidity and mortality. Such outcome improvements would clearly provide benefits to patients, providers and payers. To date, there is scant research examining whether intensive insulin therapy for tight control of blood glucose in the perioperative period can alter outcomes for the non cardiac surgery population. The purpose of this study is to determine whether intensive insulin therapy for tight control of blood glucose in the perioperative period in non cardiac major surgery patients is associated with altered morbidity and mortality rates.

Condition or disease	Intervention/treatment	Phase
Hyperglycemia	Procedure: intensive glycemic control; Drug: conventional glycemic control	Not Applicable

Detailed Description:

Intensive insulin therapy to control blood glucose levels reduces morbidity and mortality in intensive care unit patients and in cardiac surgical patients but its role in patients undergoing non-emergent non-cardiac surgery is unknown. Benefits of glucose control may result from prevention of immune system dysfunction, reduction in systemic inflammation, and protection of endothelium and mitochondrial structure and function, all of which are known to be altered by high stress states such as that induced by surgical procedures.

In a prospective, randomized, controlled study of adult patients admitted to our operating suite for non-emergent non-cardiac surgery, we propose to correlate in-hospital morbidity and mortality with blood glucose levels of patients who are expected to have moderate to high levels of physiologic stress as a result of their pre-existing medical conditions or as a result of the proposed surgical procedure. Specifically, patients who are deemed to be American Society of Anesthesiologists Risk Classification 1-3 or higher, or patients undergoing intermediate and high risk procedures shall be considered to have moderate to high physiologic stress.

Determination of intermediate / high risk procedures shall be according to the American College of Cardiology / American Heart Association 2002 Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery as outlined in Table 1.

Table 1. Cardiac Event Risk Stratification for Noncardiac Surgical Procedures High (Reported cardiac risk often >5%)

• Emergent major operations, particularly in the elderly
• Aortic and other major vascular surgery
• Peripheral vascular surgery
• Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss Combined incidence of cardiac death and nonfatal myocardial infarction. Further preoperative cardiac testing is not generally required. Intermediate (Reported cardiac risk generally <5%)
• Intraperitoneal and intrathoracic surgery
• Carotid endarterectomy surgery
• Head and neck surgery
• Orthopedic surgery
• Prostate surgery Low (Reported cardiac risk generally <1%):
• Endoscopic procedures
• Superficial procedures
• Cataract surgery
• Breast surgery

Prior to entering the operating suite for surgery, patients will be randomly assigned to receive either intensive insulin treatment or conventional insulin treatment. Treatment assignment will be performed using sealed envelopes, and patients stratified according to Table 2.

TABLE 2. Baseline Characteristics of Patients. Variable Intention to Treat Group P Value Male sex (%) Age (Years) Type of Surgery

• Intracranial (%)
• Head & Neck (%)
• Thoracic (%)
• Vascular (%)
• Gastrointestinal (%)
• Urologic (%)
• Orthopedic (%)
• Gynecologic (%)
• Myocutaneous (%) History of Cancer (%) History of Organ Failure before Surgery (%) Organ Failure After Surgery (%) History of Diabetes (%)
• Treated with insulin
• Treated with oral diabetic agent, diet or both

Inclusion criteria:

• Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress
• Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus
• Patients must be able to provide informed consent

Exclusion criteria:

• Cognitively impaired
• Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.
• Female patients of child bearing age who have a positive pregnancy test on admission.

In all patients, whole blood hemoglobin A1C and glucose levels will be drawn prior to induction of anesthesia. Additional whole blood glucose levels will be drawn at the time of induction of anesthesia, at skin incision, hourly throughout the operation, at emergence from anesthesia, every hour up to three hours after the completion of surgery, and then once per day until the patient is discharged from the hospital.

In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL. Adjustments will be made according to the University Hospital's ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 80 mg/dL, the insulin infusion will be tapered and discontinued. For patients going to the ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management.

In the conventional treatment group, continuous insulin infusion will be started when the blood glucose level exceeds 200 mg/dL and will be adjusted to maintain the blood glucose level between 180 and 200 mg/dL. Adjustments will be made according to a modified ICU Adult Insulin Infusion Protocol. When the blood glucose level falls below 180mg/dL, the insulin infusion will be tapered and discontinued. For patients transferred to an ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being transferred to an ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery. The University Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be adopted for continued glucose management.

How will the study be analyzed?

At baseline, data on demographic and clinical characteristics of the patients (see Table 1) will be obtained. Blood will be systematically sampled and whole blood glucose levels determined as described above. All blood glucose values will be tabulated from baseline through end of study.

A research associate blinded to the treatment groups will determine morbidity and mortality by reviewing the patient's medical record upon discharge from the hospital and recording the occurrence of morbidity and mortality by the following criteria:

1. Post-operative surgical wound infection - a clinical condition requiring antibiotic treatment beyond the UH Surgical Infection Prevention (SIP) protocol and / or subsequent wound drainage / debridement
2. Systemic infection - presence of bacteremia or prolonged (i.e. greater than 10 days) use of antibiotics
3. Myocardial Injury - postoperative EKG changes that reveal new Q waves or S-T segment elevations greater than 1mm in any lead(s) or serum troponin levels that exceed….
4. Malignant arrhythmia - asystole, ventricular tachycardia or fibrillation requiring cardiopulmonary resuscitation, antiarrhythmia therapy, or defibrillator implantation
5. Respiratory Injury - mechanical ventilation for more than 48 hours, reintubation, or planned tracheostomy
6. Neurological Injury - focal brain injury with permanent functional deficit, irreversible encephalopathy
7. Renal Injury - a level of serum creatinine twice that present on admission to the hospital or acute renal failure requiring dialysis
8. Hepatic Injury - bilirubin level of >3mg per deciliter
9. Venous Thromboembolism - deposition of thrombus in peripheral or central veins as determined by Doppler ultrasonography, angiography or computed tomography.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 56 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality
• Study Start Date: June 2007
• Actual Primary Completion Date: January 2009
• Actual Study Completion Date: January 2009

Arms and Interventions

Arm	Intervention/treatment
Experimental: intensive glycemic control; In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.	Procedure: intensive glycemic control; intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl; Other Name: Novo Regular Insulin
Active Comparator: conventional glycemic control; In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL	Drug: conventional glycemic control; Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl

Outcome Measures

Primary Outcome Measures :

1. Wound Infection [ Time Frame: 7-10 days post op ]

Secondary Outcome Measures :

1. Hemodynamic Instability [ Time Frame: 0-48 hours post op ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 95 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress
• Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus
• Patients must be able to provide informed consent

Exclusion Criteria:

• Cognitively impaired
• Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.
• Female patients of child bearing age who have a positive pregnancy test on admission.

Contacts and Locations

Locations

United States, New Jersey

University Hospital

Newark, New Jersey, United States, 07107

Sponsors and Collaborators

University of Medicine and Dentistry of New Jersey

Investigators

• Principal Investigator: J Jeffery Freda, MD, MBA; Rutgers, The State University of New Jersey

More Information

Publications:

van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.

Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003 May;125(5):1007-21.

Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, Bonnet N, Riou B, Coriat P. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005 Oct;103(4):687-94.

• Responsible Party: University of Medicine and Dentistry of New Jersey
• ClinicalTrials.gov Identifier: NCT00487162
• Other Study ID Numbers: 0120070093
• First Posted: June 15, 2007
• Results First Posted: April 3, 2014
• Last Update Posted: November 8, 2016
• Last Verified: September 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Rutgers, The State University of New Jersey ( University of Medicine and Dentistry of New Jersey ):

glycemic control, diabetes, obesity, comorbidities

Additional relevant MeSH terms:

Hyperglycemia; Glucose Metabolism Disorders; Metabolic Diseases; Insulin; Hypoglycemic Agents; Physiological Effects of Drugs